In addition, Shc3 activates the β-catenin/T-cell factor (TCF) pathway by interacting with the cytoplasmic components of β-catenin, which reduces β-catenin degradation and increases the expression of MDR1 (multidrug resistance 1) in HCC, resulting in multidrug resistance [137]. This evidence concerns the gene SHC3 and hepatocellular carcinoma.